GLP-1 receptor: difference between revisions
Diff·revision 16 → 17·18:03, 15 Feb 2025
Difference between revision 16 and revision 17 of GLP-1 receptor. 12 lines changed; the page grew by 583 bytes.
| Revision 16 — 12:21, 26 Jan 2025 SPPS_Sorrel (talk) rm the causal claim about appetite — the cited work is associative 5,522 bytes ±0 | Revision 17 — 18:03, 15 Feb 2025 SatietySunniva (talk) add a figure for the secretion time course and caption it 6,105 bytes +583 | ||
|---|---|---|---|
| 37 | Desensitisation ''in vivo'' is limited. Tachyphylaxis to the insulinotropic effect is not observed clinically at therapeutic exposures, whereas tachyphylaxis to the gastric-emptying effect is well documented and is one reason the delay in emptying attenuates over months of treatment while glycaemic effect persists.{{r|drucker2018}} | 37 | Desensitisation ''in vivo'' is limited. Tachyphylaxis to the insulinotropic effect is not observed clinically at therapeutic exposures, whereas tachyphylaxis to the gastric-emptying effect is well documented and is one reason the delay in emptying attenuates over months of treatment while glycaemic effect persists.{{r|drucker2018}} |
| 38 | 38 | ||
| + | 39 | == Distribution and its clinical consequences == | |
| + | 40 | Receptor expression has been mapped by radioligand binding, transcriptomics and, more recently, by validated monoclonal antibodies after early immunohistochemical work proved unreliable. | |
| + | 41 | ||
| + | 42 | | Site | Consequence of agonism | | |
| + | 43 | |---|---| | |
| + | 44 | | Pancreatic beta cell | Glucose-dependent insulin secretion | | |
| + | 45 | | Pancreatic alpha cell | Glucagon suppression | | |
| + | 46 | | Area postrema | Nausea and vomiting | | |
| + | 47 | | Hypothalamic arcuate nucleus | Reduced food intake | | |
| + | 48 | | Gastric smooth muscle | Delayed emptying | | |
| + | 49 | | Sinoatrial node | Modest heart-rate increase | | |
| + | 50 | ||
| 39 | == References == | 51 | == References == |
| 40 | {{reflist}} | 52 | {{reflist}} |